KRAS and non-small cell lung carcinoma: Indeed, one direct G12C inhibitor, sotorasib, recently gained approval by the United States Food and Drug Administration for treatment of patients with KRAS G12C-mutated NSCLC who have received at least one prior line of therapy [9].